Processa Pharmaceuticals closed its merger with Vidya Therapeutics on July 28, issuing common and Series A preferred shares to Vidya holders and targeting a tax-free reorganization. Assuming preferred conversion, Vidya holders will own about 97% pre-PIPE; a $200.0 million PIPE of Series A preferred is expected to close July 30 to fund operations into the second half of 2029 and advance Phase 2 programs in food allergy, CSU, and RMS. The company also entered stockholder support and 180-day lock-up agreements and granted PIPE investors registration rights. Separately, Processa ended its Elion license for PCS6422 via a settlement, returning the program, paying $650,000, and providing a contingent 7.5% NewCo equity grant.

Agreement 1: Processa Pharmaceuticals Completes Merger With Vidya Therapeutics, Reshaping Ownership Structure

  • Agreement type: Agreement and Plan of Merger
  • Counterparty: Vidya Therapeutics
  • Signed / Effective: Jul 28 2026 / Jul 28 2026
  • Duration / Termination: At will
  • Reason: Combine pipelines and strengthen growth prospects

Agreement 2: Processa Pharmaceuticals Enters Support Agreements to Back Post-Merger Shareholder Votes

  • Agreement type: Stockholder Support Agreements
  • Counterparty: Company Officers and Directors
  • Signed / Effective: Jul 28 2026 / Jul 28 2026
  • Duration / Termination: Until stockholder vote
  • Reason: Facilitate approval of post-merger stockholder matters

Agreement 3: Processa Pharmaceuticals Implements 180-Day Lock-Ups for Insiders Following Vidya Merger

  • Agreement type: Lock-Up Agreements
  • Counterparty: Vidya Insiders and Processa Directors and Officers
  • Signed / Effective: Jul 28 2026 / Jul 28 2026
  • Duration / Termination: 180 days
  • Reason: Support post-merger trading stability

Agreement 4: Processa Pharmaceuticals Secures $200 Million PIPE Through Series A Preferred Sale

  • Agreement type: Securities Purchase Agreement (Private Placement of Series A Preferred)
  • Counterparty: Investors
  • Signed / Effective: Jul 28 2026 / Jul 30 2026
  • Duration / Termination: At will
  • Reason: Fund operations and key clinical milestones into 2029

Agreement 5: Processa Pharmaceuticals Grants Registration Rights to PIPE Investors

  • Agreement type: Registration Rights Agreement
  • Counterparty: Investors
  • Signed / Effective: Jul 30 2026 / Jul 30 2026
  • Duration / Termination: Until resale registration is effective
  • Reason: Provide liquidity pathway for PIPE investors

Agreement 6: Processa Pharmaceuticals Ends Elion License, Returns PCS6422 and Pays $650,000 in Settlement

  • Agreement terminated: License Agreement for PCS6422
  • Counterparty: Elion Oncology
  • Original agreement date: Aug 23 2020
  • Termination date: Jul 23 2026
  • Termination type: mutual
  • Exit fees / payments: $650,000 and potential 7.5% NewCo equity
  • Reason: Settle litigation and return PCS6422 to Elion

Original SEC Filing:

This is an AI-powered summary. It may contain inaccuracies. Consider verifying important information with the source. Please note this summary is solely based on documents filed with the SEC.